Shire Share Discussion Threads

[philanderer] 18/5/2017 16:21

That was a bit of a letdown . Analyst meeting not gone down too well by the look of it.

[broadwood] 18/5/2017 13:26

Shire has announced positive topline Phase 3 results for the HELP study that evaluated the efficacy and safety of subcutaneously administered lanadelumab versus placebo over 26 weeks in patients 12 years of age or older with Hereditary Angioedema (HAE).

Lanadelumab is an investigational treatment being evaluated for the prevention of angioedema attacks in patients with HAE, a rare genetic disease characterized by recurrent swelling of extremities, gastrointestinal tract, and upper airways.

The Company said the study met its primary endpoint and all secondary endpoints with highly statistically significant and clinically meaningful results for all three lanadelumab treatment arms compared to placebo.

The 300 mg dose administered once every two weeks resulted in a statistically significant reduction in mean HAE attack frequency of 87% compared to placebo (p <0.001).

Results were consistent regardless of baseline attack rate. Notably for each of the three lanadelumab regimens studied, whether administered biweekly or monthly, a significantly higher proportion of patients compared to placebo were attack free throughout the entire 26 week study period.

This study was representative of the full HAE disease spectrum. Overall, 52% of patients experienced three or more attacks per month at baseline, 65% of patients reported a history of laryngeal attacks and 56% were on long-term prophylaxis (LTP). Ninety percent of patients completed the study. Ninety-six percent of those who completed the study chose to roll-over into the ongoing long-term safety study (HELP" Study Extension).

"In the U.S., available treatment options include either injections for acute attacks or short-acting intravenous infusions administered twice a week," said Aleena Banerji, M.D., Massachusetts General Hospital, Boston, MA and clinical trial investigator.

"If approved, lanadelumab may offer patients a long-acting treatment option that significantly reduces HAE attacks when administered subcutaneously as infrequently as every four weeks."

"We are extremely encouraged by these topline Phase 3 results," said Flemming Ornskov, M.D., M.P.H., Shire Chief Executive Officer.

"We have nearly a decade of experience and a strong portfolio and pipeline in HAE and believe these data demonstrate high potential for transforming the way patients living with this condition are treated."

[philanderer] 18/5/2017 13:26

See what happens after analysts meeting at 3pm today.

[jovi1] 18/5/2017 12:42

ready for a pull back before it really rise?
I am not expert by long way but this smell as blockbuster

[jovi1] 18/5/2017 12:18

agree

nice day to do it

[philanderer] 18/5/2017 12:13

Well that's put the portfolio into the blue today :-)

[philanderer] 18/5/2017 12:12

Here we go..


Shire : Positive lanadelumab topline Phase 3 results

05/18/2017 | 01:09pm CEST

Shire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial
Significant reduction in monthly Hereditary Angioedema (HAE) attack rate with infrequent subcutaneous administration
Data to serve as basis for U.S. BLA filing expected in Q4 2017 to Q1 2018

Shire to host Investor Call today at 10 a.m. ET; details below

[philanderer] 18/5/2017 12:09

Just noticed jovi :-O

Maybe a fat finger ? We`ll see.

[jovi1] 18/5/2017 12:06

anyone any idea why the jump?

[philanderer] 17/5/2017 09:02

17th may Citigroup buy

reiterates

[philanderer] 16/5/2017 17:07

Shire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association

[philanderer] 12/5/2017 13:29

updated:

11th may Berenberg buy tp 5900p
4th may Citigroup buy tp 6500p
3rd may HSBC hold tp 4550p
3rd may Deutsche buy tp 6300p
3rd may Goldman Sachs buy tp 6800p
3rd may Credit Suisse outperform tp 5400p
3rd may JP Morgan overweight tp 6000p
3rd may Liberum buy tp 5500p
3rd may Jefferies buy tp 6400p
3rd may Barclays overweight tp 6500p

3rd may ++++ Results ++++

[philanderer] 12/5/2017 08:51

But promising today ... AZN news leading the way

[philanderer] 11/5/2017 13:10

Seems resistance is at 4700p

[philanderer] 09/5/2017 14:09

Investors Chronicle:

First-quarter earnings from the UK's big three pharma groups are in and - on a headline basis at least - there's a clear winner. Shire (SHP) not only beat consensus analyst expectations by 7 per cent with its triple-digit top-line growth, but also managed to progress the integration of its mammoth Baxalta acquisition ahead of schedule.

IC VIEW:
Investors have displayed a distinct lack of belief in AstraZeneca and Shire during the past 12 months and their shares have struggled. Given the strength in both of these companies' pipelines we think this is unjustified and rate both a buy. GSK's dividend makes it a solid holding, but the long-term outlook is less exciting than that of its peers.

[philanderer] 08/5/2017 20:47

Shire subsidiary sues Genentech and Chugai

[philanderer] 08/5/2017 15:45

That was a bit previous , back to pre results level now.

[philanderer] 04/5/2017 12:03

4th may Citigroup buy tp 6500p


"It's Time To Buy Shire"

[philanderer] 03/5/2017 17:36

3rd may HSBC hold tp 4550p
3rd may Deutsche buy tp 6300p
3rd may Goldman Sachs buy tp 6800p
3rd may Credit Suisse outperform tp 5400p
3rd may JP Morgan overweight tp 6000p
3rd may Liberum buy tp 5500p
3rd may Jefferies buy tp 6400p
3rd may Barclays overweight tp 6500p

[philanderer] 24/4/2017 18:32

'This fast-growing pharmaceutical stock blows GlaxoSmithKline plc out of the water'